The Mechanism of Sodium-Glucose Cotransporter-2 Inhibitors in Reducing Uric Acid in Type 2 Diabetes Mellitus

References

• Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14:88–98. doi:10.1038/nrendo.2017.151
   PubMed Web of Science ®Google Scholar
• Chen YY, Kao TW, Yang HF, et al. The association of uric acid with the risk of metabolic syndrome, arterial hypertension or diabetes in young subjects- An observational study. Clin Chim Acta. 2018;478:68–73. doi:10.1016/j.cca.2017.12.038
   PubMed Web of Science ®Google Scholar
• Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32:1737–1742. doi:10.2337/dc09-0288
   PubMed Web of Science ®Google Scholar
• Chang -C-C, Wu C-H, Liu L-K, et al. Association between serum uric acid and cardiovascular risk in nonhypertensive and nondiabetic individuals: the Taiwan I-Lan Longitudinal Aging Study. Sci Rep. 2018;8:5234.
   PubMed Web of Science ®Google Scholar
• Bombelli M, Quarti-Trevano F, Tadic M, et al. Uric acid and risk of new-onset metabolic syndrome, impaired fasting glucose and diabetes mellitus in a general Italian population: data from the Pressioni Arteriose Monitorate E Loro Associazioni study. J Hypertens. 2018;36:1492–1498. doi:10.1097/HJH.0000000000001721
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Fogacci F, Giovannini M, et al. Serum uric acid predicts incident metabolic syndrome in the elderly in an analysis of the Brisighella Heart Study. Sci Rep. 2018;8. doi:10.1038/s41598-018-29955-w
   Web of Science ®Google Scholar
• Ali N, Mahmood S, Islam F, et al. Relationship between serum uric acid and hypertension: a cross-sectional study in Bangladeshi adults. Sci Rep. 2019;9:9061. doi:10.1038/s41598-019-45680-4
   PubMed Web of Science ®Google Scholar
• Li L, Yang C, Zhao Y, et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15:1–12. doi:10.1186/1471-2369-15-122
   PubMed Web of Science ®Google Scholar
• Chen J, Williams S, Ho S, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 2010;1:57–92. doi:10.1007/s13300-010-0006-4
   PubMedGoogle Scholar
• Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015;12:78–89. doi:10.1177/1479164114561992
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8:495–502. doi:10.1038/nrendo.2011.243
   PubMed Web of Science ®Google Scholar
• Khat DZ, Husain M. Molecular mechanisms underlying the cardiovascular benefits of SGLT2i and GLP-1RA. Curr Diab Rep. 2018;18:45. doi:10.1007/s11892-018-1011-7
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31–39. doi:10.1016/S0140-6736(18)32590-X
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:422–434. doi:10.1016/j.jacc.2019.11.031
   PubMed Web of Science ®Google Scholar
• Maiuolo J, Oppedisano F, Gratteri S, Muscoli C, Mollace V. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016;213:8–14. doi:10.1016/j.ijcard.2015.08.109
   PubMed Web of Science ®Google Scholar
• Bobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis. 2012;19:358–371. doi:10.1053/j.ackd.2012.07.009
   PubMed Web of Science ®Google Scholar
• Xiong Q, Liu J, Xu Y. Effects of uric acid on diabetes mellitus and its chronic complications. Int J Endocrinol. 2019;2019:9691345. doi:10.1155/2019/9691345
   PubMed Web of Science ®Google Scholar
• Murea M, Tucker BM. The physiology of uric acid and the impact of end-stage kidney disease and dialysis. Semin Dial. 2019;32:47–57. doi:10.1111/sdi.12735
   PubMed Web of Science ®Google Scholar
• Lipkowitz MS. Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep. 2012;14:179–188. doi:10.1007/s11926-012-0240-z
   PubMed Web of Science ®Google Scholar
• Nigam SK, Bhatnagar V. The systems biology of uric acid transporters. Curr Opin Nephrol Hypertens. 2018;27:305–313. doi:10.1097/MNH.0000000000000427
   PubMed Web of Science ®Google Scholar
• Xu L, Shi Y, Zhuang S, Liu N. Recent advances on uric acid transporters. Oncotarget. 2017;8:100852–100862. doi:10.18632/oncotarget.20135
   PubMedGoogle Scholar
• Mulla MJ, Myrtolli K, Potter J, et al. Uric acid induces trophoblast IL-1beta production via the inflammasome: implications for the pathogenesis of preeclampsia. Am J Reprod Immunol. 2011;65:542–548. doi:10.1111/j.1600-0897.2010.00960.x
   PubMed Web of Science ®Google Scholar
• Ruggiero C, Cherubini A, Ble A, et al. Uric acid and inflammatory markers. Eur Heart J. 2006;27:1174–1181. doi:10.1093/eurheartj/ehi879
   PubMed Web of Science ®Google Scholar
• Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005;25:39–42. doi:10.1016/j.semnephrol.2004.09.007
   PubMed Web of Science ®Google Scholar
• Garibotto G, Carta A, Picciotto D, Viazzi F, Verzola D. Toll-like receptor-4 signaling mediates inflammation and tissue injury in diabetic nephropathy. J Nephrol. 2017;30:719–727. doi:10.1007/s40620-017-0432-8
   PubMed Web of Science ®Google Scholar
• Wada J, Makino H. Innate immunity in diabetes and diabetic nephropathy. Nat Rev Nephrol. 2016;12:13–26. doi:10.1038/nrneph.2015.175
   PubMed Web of Science ®Google Scholar
• Gersch C, Palii SP, Kim KM, et al. Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids. 2008;27(8):967–978. doi:10.1080/15257770802257952
   PubMed Web of Science ®Google Scholar
• Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67:1739–1742. doi:10.1111/j.1523-1755.2005.00273.x
   PubMed Web of Science ®Google Scholar
• Wang XD, Liu J, Zhang YC, et al. Correlation between the elevated uric acid levels and circulating renin-angiotensin-aldosterone system activation in patients with atrial fibrillation. Cardiovasc Diagn Ther. 2021;11:50–55. doi:10.21037/cdt-20-830
   PubMed Web of Science ®Google Scholar
• Sanchez-Lozada LG, Lanaspa MA, Cristobal-Garcia M, et al. Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol. 2012;121:e71–e78. doi:10.1159/000345509
   PubMedGoogle Scholar
• Ko J, Kang HJ, Kim DA, et al. Uric acid induced the phenotype transition of vascular endothelial cells via induction of oxidative stress and glycocalyx shedding. FASEB J. 2019;33:13334–13345. doi:10.1096/fj.201901148R
   PubMed Web of Science ®Google Scholar
• Doehner W, Landmesser U. Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options. Semin Nephrol. 2011;31:433–440. doi:10.1016/j.semnephrol.2011.08.007
   PubMed Web of Science ®Google Scholar
• Lanaspa MA, Sanchez-Lozada LG, Choi YJ, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem. 2012;287:40732–40744. doi:10.1074/jbc.M112.399899
   PubMed Web of Science ®Google Scholar
• Landmesser U, Spiekermann S, Preuss C, et al. Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc Biol. 2007;27:943–948. doi:10.1161/01.ATV.0000258415.32883.bf
   PubMed Web of Science ®Google Scholar
• Hurrle S, Hsu WH. The etiology of oxidative stress in insulin resistance. Biomed J. 2017;40:257–262. doi:10.1016/j.bj.2017.06.007
   PubMed Web of Science ®Google Scholar
• Ni L, Yuan C, Chen G, Zhang C, Wu X. SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020;19:98. doi:10.1186/s12933-020-01071-y
   PubMed Web of Science ®Google Scholar
• McDowell K, Welsh P, Docherty KF, et al. Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. Eur J Heart Fail. 2022;24(6):1066–1076. doi:10.1002/ejhf.2433
   PubMed Web of Science ®Google Scholar
• Hao Z, Huang X, Shao H, Tian F. Effects of dapagliflozin on serum uric acid levels in hospitalized type 2 diabetic patients with inadequate glycemic control: a randomized controlled trial. Ther Clin Risk Manag. 2018;14:2407–2413. doi:10.2147/TCRM.S186347
   PubMed Web of Science ®Google Scholar
• Ferreira JP, Inzucchi SE, Mattheus M, et al. Empagliflozin and uric acid metabolism in diabetes: a post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2022;24:135–141. doi:10.1111/dom.14559
   PubMed Web of Science ®Google Scholar
• Davies MJ, Trujillo A, Vijapurkar U, Damaraju CV, Meininger G. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17:426–429. doi:10.1111/dom.12439
   PubMed Web of Science ®Google Scholar
• Suijk DL, van Baar MJ, van Bommel EJ, et al. SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function. Clin J Am Soc Nephrol. 2022;17:663–671. doi:10.2215/CJN.11480821
   PubMed Web of Science ®Google Scholar
• Lund LC, Hojlund M, Henriksen DP, Hallas J, Kristensen KB. Sodium-glucose cotransporter-2 inhibitors and the risk of gout: a Danish population based cohort study and symmetry analysis. Pharmacoepidemiol Drug Saf. 2021;30:1391–1395. doi:10.1002/pds.5252
   PubMed Web of Science ®Google Scholar
• Fralick M, Chen SK, Patorno E, Kim SC. Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study. Ann Intern Med. 2020;172:186–194. doi:10.7326/M19-2610
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xu L, Tian D, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20:458–462. doi:10.1111/dom.13101
   PubMed Web of Science ®Google Scholar
• Mancikova A, Krylov V, Hurba O, et al. Functional analysis of novel allelic variants in URAT1 and GLUT9 causing renal hypouricemia type 1 and 2. Clin Exp Nephrol. 2016;20:578–584. doi:10.1007/s10157-015-1186-z
   PubMed Web of Science ®Google Scholar
• Toyoda Y, Kawamura Y, Nakayama A, et al. Substantial anti-gout effect conferred by common and rare dysfunctional variants of URAT1/SLC22A12. Rheumatology. 2021;60:5224–5232. doi:10.1093/rheumatology/keab327
   PubMed Web of Science ®Google Scholar
• Caulfield MJ, Munroe PB, O’Neill D, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med. 2008;5:e197. doi:10.1371/journal.pmed.0050197
   PubMed Web of Science ®Google Scholar
• Matsuo H, Chiba T, Nagamori S, et al. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet. 2008;83:744–751. doi:10.1016/j.ajhg.2008.11.001
   PubMed Web of Science ®Google Scholar
• Novikov A, Fu Y, Huang W, et al. SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1. Am J Physiol Renal Physiol. 2019;316:F173–F185. doi:10.1152/ajprenal.00462.2018
   PubMed Web of Science ®Google Scholar
• Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35:391–404. doi:10.1002/bdd.1909
   PubMed Web of Science ®Google Scholar
• Kimura T, Takahashi M, Yan K, Sakurai H, Kanzaki M. Expression of SLC2A9 isoforms in the kidney and their localization in polarized epithelial cells. PLoS One. 2014;9(1):e84996. doi:10.1371/journal.pone.0084996
   PubMed Web of Science ®Google Scholar
• Clarke NE, Belyaev ND, Lambert DW, Turner AJ. Epigenetic regulation of angiotensin-converting enzyme 2 (ACE2) by SIRT1 under conditions of cell energy stress. Clin Sci. 2014;126:507–516. doi:10.1042/CS20130291
   Web of Science ®Google Scholar
• Umino H, Hasegawa K, Minakuchi H, et al. High basolateral glucose increases sodium-glucose cotransporter 2 and reduces sirtuin-1 in renal tubules through glucose transporter-2 detection. Sci Rep. 2018;8:6791. doi:10.1038/s41598-018-25054-y
   PubMed Web of Science ®Google Scholar
• Battelli MG, Bortolotti M, Polito L, Bolognesi A. The role of xanthine oxidoreductase and uric acid in metabolic syndrome. Biochim Biophys Acta Mol Basis Dis. 2018;1864:2557–2565. doi:10.1016/j.bbadis.2018.05.003
   PubMed Web of Science ®Google Scholar
• Washio KW, Kusunoki Y, Murase T, et al. Xanthine oxidoreductase activity is correlated with insulin resistance and subclinical inflammation in young humans. Metabolism. 2017;70:51–56. doi:10.1016/j.metabol.2017.01.031
   PubMed Web of Science ®Google Scholar
• Ahmed MI, Gladden JD, Litovsky SH, et al. Increased oxidative stress and cardiomyocyte myofibrillar degeneration in patients with chronic isolated mitral regurgitation and ejection fraction >60%. J Am Coll Cardiol. 2010;55:671–679. doi:10.1016/j.jacc.2009.08.074
   PubMed Web of Science ®Google Scholar
• Huang XF, Li HQ, Shi L, et al. Synthesis of resveratrol analogues, and evaluation of their cytotoxic and xanthine oxidase inhibitory activities. Chem Biodivers. 2008;5:636–642.
   PubMed Web of Science ®Google Scholar
• Packer M. Uric acid is a biomarker of oxidative stress in the failing heart: lessons learned from trials with allopurinol and SGLT2 inhibitors. J Card Fail. 2020;26:977–984. doi:10.1016/j.cardfail.2020.08.015
   PubMed Web of Science ®Google Scholar
• Wang J, Zhu XX, Liu L, et al. SIRT1 prevents hyperuricemia via the PGC-1alpha/PPARgamma-ABCG2 pathway. Endocrine. 2016;53:443–452. doi:10.1007/s12020-016-0896-7
   PubMed Web of Science ®Google Scholar
• Braga TT, Forni MF, Correa-Costa M, et al. Soluble uric acid activates the NLRP3 inflammasome. Sci Rep. 2017;7:39884. doi:10.1038/srep39884
   PubMed Web of Science ®Google Scholar
• McDermott M, Kingsbury S, Conaghan PG. The role of the NLRP3 inflammasome in gout. J Inflamm Res. 2011;39–49. doi:10.2147/JIR.S11330
   PubMedGoogle Scholar
• Matsuo H, Takada T, Ichida K, et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci Transl Med. 2009;1:5ra11. doi:10.1126/scitranslmed.3000237
   PubMed Web of Science ®Google Scholar
• Chen M, Lu X, Lu C, et al. Soluble uric acid increases PDZK1 and ABCG2 expression in human intestinal cell lines via the TLR4-NLRP3 inflammasome and PI3K/Akt signaling pathway. Arthritis Res Ther. 2018;20. doi:10.1186/s13075-018-1512-4
   Web of Science ®Google Scholar
• Kim SR, Lee SG, Kim SH, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020;11:2127. doi:10.1038/s41467-020-15983-6
   PubMed Web of Science ®Google Scholar
• Lee TM, Lin SZ, Chang NC. Effects of urate-lowering agents on arrhythmia vulnerability in post-infarcted rat hearts. J Pharmacol Sci. 2016;131:28–36. doi:10.1016/j.jphs.2016.03.009
   PubMed Web of Science ®Google Scholar
• Herat LY, Matthews J, Azzam O, Schlaich MP, Matthews VB. Targeting features of the metabolic syndrome through sympatholytic effects of SGLT2 inhibition. Curr Hypertens Rep. 2022;24:67–74. doi:10.1007/s11906-022-01170-z
   PubMed Web of Science ®Google Scholar
• Yaribeygi H, Atkin SL, Butler AE, Sahebkar A. Sodium-glucose cotransporter inhibitors and oxidative stress: an update. J Cell Physiol. 2019;234:3231–3237. doi:10.1002/jcp.26760
   PubMed Web of Science ®Google Scholar
• Osorio H, Coronel I, Arellano A, et al. Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats. Oxid Med Cell Longev. 2012;2012:542042. doi:10.1155/2012/542042
   PubMed Web of Science ®Google Scholar